SI3250691T1 - Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo - Google Patents

Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo

Info

Publication number
SI3250691T1
SI3250691T1 SI201631744T SI201631744T SI3250691T1 SI 3250691 T1 SI3250691 T1 SI 3250691T1 SI 201631744 T SI201631744 T SI 201631744T SI 201631744 T SI201631744 T SI 201631744T SI 3250691 T1 SI3250691 T1 SI 3250691T1
Authority
SI
Slovenia
Prior art keywords
methods
hybrid dna
rna polynucleotides
crispr
crispr hybrid
Prior art date
Application number
SI201631744T
Other languages
English (en)
Slovenian (sl)
Inventor
Andrew P. May
Paul D. Donohoue
Original Assignee
Caribou Biosciences, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Caribou Biosciences, Inc. filed Critical Caribou Biosciences, Inc.
Publication of SI3250691T1 publication Critical patent/SI3250691T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/10—Processes for the isolation, preparation or purification of DNA or RNA
    • C12N15/102—Mutagenizing nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/82—Vectors or expression systems specially adapted for eukaryotic hosts for plant cells, e.g. plant artificial chromosomes (PACs)
    • C12N15/8201—Methods for introducing genetic material into plant cells, e.g. DNA, RNA, stable or transient incorporation, tissue culture methods adapted for transformation
    • C12N15/8213—Targeted insertion of genes into the plant genome by homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6813—Hybridisation assays
    • C12Q1/6827—Hybridisation assays for detection of mutation or polymorphism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y301/00—Hydrolases acting on ester bonds (3.1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPR]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/50—Physical structure
    • C12N2310/53—Physical structure partially self-complementary or closed
    • C12N2310/531—Stem-loop; Hairpin
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/51—Methods for regulating/modulating their activity modulating the chemical stability, e.g. nuclease-resistance
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/50—Methods for regulating/modulating their activity
    • C12N2320/53—Methods for regulating/modulating their activity reducing unwanted side-effects
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Mycology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Analytical Chemistry (AREA)
  • Crystallography & Structural Chemistry (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Saccharide Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
SI201631744T 2015-01-28 2016-01-27 Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo SI3250691T1 (sl)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562108931P 2015-01-28 2015-01-28
US201562251548P 2015-11-05 2015-11-05
EP16704978.2A EP3250691B9 (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use
PCT/US2016/015145 WO2016123230A1 (en) 2015-01-28 2016-01-27 Crispr hybrid dna/rna polynucleotides and methods of use

Publications (1)

Publication Number Publication Date
SI3250691T1 true SI3250691T1 (sl) 2023-10-30

Family

ID=55361965

Family Applications (1)

Application Number Title Priority Date Filing Date
SI201631744T SI3250691T1 (sl) 2015-01-28 2016-01-27 Hibridni dna/rna-polinukleotidi crispr in postopki za uporabo

Country Status (27)

Country Link
US (11) US9650617B2 (enExample)
EP (2) EP3250691B9 (enExample)
JP (2) JP6835726B2 (enExample)
KR (4) KR20190112855A (enExample)
CN (2) CN107810270A (enExample)
AU (3) AU2016211517B2 (enExample)
BR (1) BR112017016080B1 (enExample)
CA (2) CA3060508C (enExample)
DK (1) DK3250691T5 (enExample)
ES (1) ES2955957T3 (enExample)
FI (1) FI3250691T3 (enExample)
GB (1) GB2550745A (enExample)
HR (1) HRP20231022T1 (enExample)
HU (1) HUE063813T2 (enExample)
IL (4) IL288263B (enExample)
LT (1) LT3250691T (enExample)
MX (2) MX2017009506A (enExample)
NZ (1) NZ733702A (enExample)
PL (1) PL3250691T3 (enExample)
PT (1) PT3250691T (enExample)
RS (1) RS64527B1 (enExample)
RU (1) RU2713328C2 (enExample)
SG (3) SG11201705788TA (enExample)
SI (1) SI3250691T1 (enExample)
SM (1) SMT202300341T1 (enExample)
WO (1) WO2016123230A1 (enExample)
ZA (2) ZA201705174B (enExample)

Families Citing this family (157)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2013010911A (es) 2011-03-23 2015-03-03 Pioneer Hi Bred Int Metodos para producir un locus de rasgo transgenico complejo.
EP2734621B1 (en) 2011-07-22 2019-09-04 President and Fellows of Harvard College Evaluation and improvement of nuclease cleavage specificity
US10760064B2 (en) 2013-03-15 2020-09-01 The General Hospital Corporation RNA-guided targeting of genetic and epigenomic regulatory proteins to specific genomic loci
KR102405549B1 (ko) 2013-03-15 2022-06-08 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
SMT202100516T1 (it) 2013-04-16 2021-11-12 Regeneron Pharma Modificazione mirata del genoma di ratto
US20150044192A1 (en) 2013-08-09 2015-02-12 President And Fellows Of Harvard College Methods for identifying a target site of a cas9 nuclease
US9359599B2 (en) 2013-08-22 2016-06-07 President And Fellows Of Harvard College Engineered transcription activator-like effector (TALE) domains and uses thereof
MX363842B (es) 2013-08-22 2019-04-05 Du Pont Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
US9340799B2 (en) 2013-09-06 2016-05-17 President And Fellows Of Harvard College MRNA-sensing switchable gRNAs
US9388430B2 (en) 2013-09-06 2016-07-12 President And Fellows Of Harvard College Cas9-recombinase fusion proteins and uses thereof
US9526784B2 (en) 2013-09-06 2016-12-27 President And Fellows Of Harvard College Delivery system for functional nucleases
BR112016013400B1 (pt) 2013-12-11 2023-02-14 Regeneron Pharmaceuticals, Inc. Método in vitro para modificar um genoma em um lócus genômico de interesse em uma célula pluripotente
US11053481B2 (en) 2013-12-12 2021-07-06 President And Fellows Of Harvard College Fusions of Cas9 domains and nucleic acid-editing domains
WO2016022363A2 (en) 2014-07-30 2016-02-11 President And Fellows Of Harvard College Cas9 proteins including ligand-dependent inteins
CA2956487A1 (en) 2014-09-12 2016-03-17 E. I. Du Pont De Nemours And Company Generation of site-specific-integration sites for complex trait loci in corn and soybean, and methods of use
AU2015330699B2 (en) 2014-10-10 2021-12-02 Editas Medicine, Inc. Compositions and methods for promoting homology directed repair
GB201418965D0 (enExample) 2014-10-24 2014-12-10 Ospedale San Raffaele And Fond Telethon
CA2963820A1 (en) 2014-11-07 2016-05-12 Editas Medicine, Inc. Methods for improving crispr/cas-mediated genome-editing
LT3250691T (lt) 2015-01-28 2023-09-11 Caribou Biosciences, Inc. Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai
CN107567499A (zh) 2015-03-27 2018-01-09 纳幕尔杜邦公司 大豆u6核小rna基因启动子及其在植物小rna基因的组成型表达中的用途
GB201506509D0 (en) 2015-04-16 2015-06-03 Univ Wageningen Nuclease-mediated genome editing
US11390884B2 (en) 2015-05-11 2022-07-19 Editas Medicine, Inc. Optimized CRISPR/cas9 systems and methods for gene editing in stem cells
CN116334142A (zh) 2015-06-09 2023-06-27 爱迪塔斯医药公司 用于改善移植的crispr/cas相关方法和组合物
US20160362667A1 (en) * 2015-06-10 2016-12-15 Caribou Biosciences, Inc. CRISPR-Cas Compositions and Methods
US9790490B2 (en) * 2015-06-18 2017-10-17 The Broad Institute Inc. CRISPR enzymes and systems
US10648020B2 (en) 2015-06-18 2020-05-12 The Broad Institute, Inc. CRISPR enzymes and systems
AU2016285724A1 (en) 2015-06-29 2017-11-16 Ionis Pharmaceuticals, Inc. Modified CRISPR RNA and modified single CRISPR RNA and uses thereof
US11279928B2 (en) 2015-06-29 2022-03-22 Massachusetts Institute Of Technology Compositions comprising nucleic acids and methods of using the same
US9926546B2 (en) 2015-08-28 2018-03-27 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
US9512446B1 (en) 2015-08-28 2016-12-06 The General Hospital Corporation Engineered CRISPR-Cas9 nucleases
WO2017053879A1 (en) 2015-09-24 2017-03-30 Editas Medicine, Inc. Use of exonucleases to improve crispr/cas-mediated genome editing
WO2017070598A1 (en) 2015-10-23 2017-04-27 Caribou Biosciences, Inc. Engineered crispr class 2 cross-type nucleic-acid targeting nucleic acids
IL294014B2 (en) 2015-10-23 2024-07-01 Harvard College Nucleobase editors and uses thereof
RU2018117360A (ru) * 2015-12-04 2020-01-09 Карибо Биосайенсиз, Инк. Сконструированные нуклеиновые кислоты, нацеленные на нуклеиновую кислоту
BR112018011503A2 (pt) 2015-12-07 2018-12-04 Zymergen Inc promotores da corynebacterium glutamicum
US9988624B2 (en) 2015-12-07 2018-06-05 Zymergen Inc. Microbial strain improvement by a HTP genomic engineering platform
CN109310784B (zh) 2015-12-07 2022-08-19 阿克生物公司 用于制备和使用指导核酸的方法和组合物
US11208649B2 (en) 2015-12-07 2021-12-28 Zymergen Inc. HTP genomic engineering platform
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
US9896696B2 (en) * 2016-02-15 2018-02-20 Benson Hill Biosystems, Inc. Compositions and methods for modifying genomes
WO2017165826A1 (en) 2016-03-25 2017-09-28 Editas Medicine, Inc. Genome editing systems comprising repair-modulating enzyme molecules and methods of their use
WO2017180694A1 (en) 2016-04-13 2017-10-19 Editas Medicine, Inc. Cas9 fusion molecules gene editing systems, and methods of use thereof
US12410416B2 (en) 2016-04-19 2025-09-09 The Broad Institute, Inc. CRISPR enzymes and systems with modified pam specificity
CN106244591A (zh) * 2016-08-23 2016-12-21 苏州吉玛基因股份有限公司 修饰crRNA在CRISPR/Cpf1基因编辑系统中的应用
EA201892810A1 (ru) 2016-06-01 2019-06-28 Квс Заат Се Гибридные последовательности нуклеиновых кислот для геномной инженерии
US10767175B2 (en) 2016-06-08 2020-09-08 Agilent Technologies, Inc. High specificity genome editing using chemically modified guide RNAs
EP3478833A4 (en) 2016-06-30 2019-10-02 Zymergen, Inc. METHOD FOR PRODUCING A BACTERIAL HEMOGLOBIN LIBRARY AND ITS USE
JP2019519241A (ja) 2016-06-30 2019-07-11 ザイマージェン インコーポレイテッド グルコース透過酵素ライブラリーを生成するための方法およびその使用
US11845929B2 (en) 2016-07-08 2023-12-19 Ohio State Innovation Foundation Modified nucleic acids, hybrid guide RNAs, and uses thereof
WO2018027078A1 (en) 2016-08-03 2018-02-08 President And Fellows Of Harard College Adenosine nucleobase editors and uses thereof
CN109804066A (zh) 2016-08-09 2019-05-24 哈佛大学的校长及成员们 可编程cas9-重组酶融合蛋白及其用途
US20190264193A1 (en) 2016-08-12 2019-08-29 Caribou Biosciences, Inc. Protein engineering methods
SG11201901306XA (en) 2016-08-19 2019-03-28 Toolgen Inc Artificially engineered angiogenesis regulatory system
WO2018039438A1 (en) 2016-08-24 2018-03-01 President And Fellows Of Harvard College Incorporation of unnatural amino acids into proteins using base editing
US11306305B2 (en) 2016-09-23 2022-04-19 Board Of Trustees Of Southern Illinois University Tuning CRISPR/Cas9 activity with chemically modified nucleotide substitutions
EP3523427A4 (en) 2016-10-07 2020-09-02 Integrated DNA Technologies, Inc. S. PYOGENES AND POLYPEPTIDES MUTANT CAS9 GENES CODED BY SUCH GENES
US11242542B2 (en) 2016-10-07 2022-02-08 Integrated Dna Technologies, Inc. S. pyogenes Cas9 mutant genes and polypeptides encoded by same
CN110214180A (zh) 2016-10-14 2019-09-06 哈佛大学的校长及成员们 核碱基编辑器的aav递送
US20180282722A1 (en) * 2016-11-21 2018-10-04 Massachusetts Institute Of Technology Chimeric DNA:RNA Guide for High Accuracy Cas9 Genome Editing
WO2018098383A1 (en) 2016-11-22 2018-05-31 Integrated Dna Technologies, Inc. Crispr/cpf1 systems and methods
US9816093B1 (en) 2016-12-06 2017-11-14 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
WO2018111947A1 (en) 2016-12-12 2018-06-21 Integrated Dna Technologies, Inc. Genome editing enhancement
EP3555297A1 (en) 2016-12-19 2019-10-23 Editas Medicine, Inc. Assessing nuclease cleavage
US10745677B2 (en) 2016-12-23 2020-08-18 President And Fellows Of Harvard College Editing of CCR5 receptor gene to protect against HIV infection
US20190382751A1 (en) * 2016-12-28 2019-12-19 Ionis Pharmaceuticals, Inc. Modified crispr rna and uses thereof
WO2018129368A2 (en) 2017-01-06 2018-07-12 Editas Medicine, Inc. Methods of assessing nuclease cleavage
EP3574101B1 (en) * 2017-01-30 2023-04-19 KWS SAAT SE & Co. KGaA Repair template linkage to endonucleases for genome engineering
WO2018165504A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Suppression of pain by gene editing
WO2018165631A1 (en) 2017-03-09 2018-09-13 President And Fellows Of Harvard College Cancer vaccine
JP2020510439A (ja) 2017-03-10 2020-04-09 プレジデント アンド フェローズ オブ ハーバード カレッジ シトシンからグアニンへの塩基編集因子
KR20240116572A (ko) 2017-03-23 2024-07-29 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 핵산 프로그램가능한 dna 결합 단백질을 포함하는 핵염기 편집제
CA3084252A1 (en) 2017-03-28 2018-10-04 Caribou Biosciences, Inc. Crispr-associated (cas) protein
WO2018201086A1 (en) 2017-04-28 2018-11-01 Editas Medicine, Inc. Methods and systems for analyzing guide rna molecules
US11560566B2 (en) 2017-05-12 2023-01-24 President And Fellows Of Harvard College Aptazyme-embedded guide RNAs for use with CRISPR-Cas9 in genome editing and transcriptional activation
CN108977442B (zh) * 2017-06-05 2023-01-06 广州市锐博生物科技有限公司 用于dna编辑的系统及其应用
EP3635113A4 (en) 2017-06-05 2021-03-17 Fred Hutchinson Cancer Research Center SAFE GENOMIC HAVERS FOR GENETIC THERAPIES IN HUMAN STEM CELLS AND NANOPARTICLES MODIFIED TO ENABLE TARGETED GENETIC THERAPIES
JP2020524490A (ja) 2017-06-06 2020-08-20 ザイマージェン インコーポレイテッド Ｅｓｃｈｅｒｉｃｈｉａ Ｃｏｌｉを改良するためのＨＴＰゲノム操作プラットフォーム
EP3635112A2 (en) 2017-06-06 2020-04-15 Zymergen, Inc. A htp genomic engineering platform for improving fungal strains
EP3635114B1 (en) * 2017-06-07 2024-11-06 Arc Bio, LLC Creation and use of guide nucleic acids
KR102746733B1 (ko) 2017-06-09 2024-12-24 에디타스 메디신, 인코포레이티드 조작된 cas9 뉴클레아제
US10907150B2 (en) 2017-06-14 2021-02-02 Wisconsin Alumni Research Foundation Modified guide RNAs, CRISPR-ribonucleotprotein complexes and methods of use
WO2019014564A1 (en) 2017-07-14 2019-01-17 Editas Medicine, Inc. SYSTEMS AND METHODS OF TARGETED INTEGRATION AND GENOME EDITING AND DETECTION THEREOF WITH INTEGRATED PRIMING SITES
CN112501254B (zh) 2017-07-14 2024-07-19 上海吐露港生物科技有限公司 一种Cas蛋白的用途及靶标核酸分子的检测方法和试剂盒
US11584955B2 (en) * 2017-07-14 2023-02-21 Shanghai Tolo Biotechnology Company Limited Application of Cas protein, method for detecting target nucleic acid molecule and kit
CN111801345A (zh) 2017-07-28 2020-10-20 哈佛大学的校长及成员们 使用噬菌体辅助连续进化(pace)的进化碱基编辑器的方法和组合物
EP3665279B1 (en) 2017-08-09 2023-07-19 Benson Hill, Inc. Compositions and methods for modifying genomes
US11319532B2 (en) 2017-08-30 2022-05-03 President And Fellows Of Harvard College High efficiency base editors comprising Gam
WO2019046540A1 (en) 2017-08-31 2019-03-07 New York Genome Center, Inc. METHODS AND COMPOSITIONS COMPRISING CRISPR-CPF1 AND APPROVED GUIDING CRISPR RNAES FOR PROGRAMMABLE GENOMIC DELETIONS
CN111757937A (zh) 2017-10-16 2020-10-09 布罗德研究所股份有限公司 腺苷碱基编辑器的用途
WO2019099943A1 (en) 2017-11-16 2019-05-23 Astrazeneca Ab Compositions and methods for improving the efficacy of cas9-based knock-in strategies
WO2019113132A1 (en) 2017-12-05 2019-06-13 Caribou Biosciences, Inc. Modified lymphocytes
EP3724216A1 (en) 2017-12-15 2020-10-21 Dana Farber Cancer Institute, Inc. Stabilized peptide-mediated targeted protein degradation
US12406749B2 (en) 2017-12-15 2025-09-02 The Broad Institute, Inc. Systems and methods for predicting repair outcomes in genetic engineering
WO2019147743A1 (en) * 2018-01-26 2019-08-01 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
WO2019152941A1 (en) 2018-02-05 2019-08-08 Caribou Biosciences, Inc. Engineered gut microbes for reduction of reactivation of detoxified drugs
US12084676B2 (en) 2018-02-23 2024-09-10 Pioneer Hi-Bred International, Inc. Cas9 orthologs
WO2019173248A1 (en) 2018-03-07 2019-09-12 Caribou Biosciences, Inc. Engineered nucleic acid-targeting nucleic acids
JP7555822B2 (ja) 2018-04-19 2024-09-25 ザ・リージエンツ・オブ・ザ・ユニバーシテイー・オブ・カリフオルニア ゲノム編集のための組成物および方法
GB2589246A (en) 2018-05-16 2021-05-26 Synthego Corp Methods and systems for guide RNA design and use
WO2019226953A1 (en) 2018-05-23 2019-11-28 The Broad Institute, Inc. Base editors and uses thereof
US12227776B2 (en) 2018-06-13 2025-02-18 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
CA3102148A1 (en) * 2018-06-13 2019-12-19 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US10227576B1 (en) 2018-06-13 2019-03-12 Caribou Biosciences, Inc. Engineered cascade components and cascade complexes
US12338436B2 (en) 2018-06-29 2025-06-24 Editas Medicine, Inc. Synthetic guide molecules, compositions and methods relating thereto
EP3820495A4 (en) 2018-07-09 2022-07-20 The Broad Institute Inc. RNA-PROGRAMMABLE EPIGENETIC RNA MODIFIERS AND THEIR USES
JP7649735B2 (ja) 2018-09-07 2025-03-21 アストラゼネカ・アクチエボラーグ 改善されたヌクレアーゼのための組成物及び方法
DK3833682T3 (da) 2018-10-01 2022-10-03 Caribou Biosciences Inc Selvmordsmolekyle sammensætninger og fremgangsmåder
KR102126573B1 (ko) 2018-10-18 2020-06-26 대한민국 CRISPR-Cas9 시스템을 이용한 유색고약버섯의 리그닌 분해효소의 유전자 편집방법 및 이의 용도
US12281338B2 (en) 2018-10-29 2025-04-22 The Broad Institute, Inc. Nucleobase editors comprising GeoCas9 and uses thereof
KR20210088615A (ko) * 2018-10-31 2021-07-14 지머젠 인코포레이티드 Dna 라이브러리의 다중 결정적 어셈블리
US11739320B2 (en) 2018-11-05 2023-08-29 Wisconsin Alumni Research Foundation Gene correction of Pompe disease and other autosomal recessive disorders via RNA-guided nucleases
EP3894550A4 (en) 2018-12-14 2023-01-04 Pioneer Hi-Bred International, Inc. NOVEL CRISPR-CAS SYSTEMS FOR GENOME EDITING
US12351837B2 (en) 2019-01-23 2025-07-08 The Broad Institute, Inc. Supernegatively charged proteins and uses thereof
GB2597377A (en) * 2019-01-25 2022-01-26 Synthego Corp Systems and methods for modulating CRISPR activity
WO2020176389A1 (en) 2019-02-25 2020-09-03 Caribou Biosciences, Inc. Plasmids for gene editing
KR20210136997A (ko) 2019-03-08 2021-11-17 지머젠 인코포레이티드 미생물에서 반복적 게놈 편집
US11053515B2 (en) 2019-03-08 2021-07-06 Zymergen Inc. Pooled genome editing in microbes
CA3130488A1 (en) 2019-03-19 2020-09-24 David R. Liu Methods and compositions for editing nucleotide sequences
US10982187B2 (en) 2019-03-26 2021-04-20 Genus Plc Bos taurus variety ‘HO840003150607238’ and methods of use thereof
US12473543B2 (en) 2019-04-17 2025-11-18 The Broad Institute, Inc. Adenine base editors with reduced off-target effects
US10975351B2 (en) 2019-06-17 2021-04-13 Abs Global, Inc. Bos taurus variety ‘JE840003146074527’ and methods of use therof
CA3153301A1 (en) * 2019-09-05 2021-03-11 Benson Hill, Inc. Compositions and methods for modifying genomes
US12435330B2 (en) 2019-10-10 2025-10-07 The Broad Institute, Inc. Methods and compositions for prime editing RNA
US20230002761A1 (en) 2019-11-19 2023-01-05 Benson Hill, Inc. Anti-bacterial crispr compositions and methods
EP4028521A1 (en) 2019-12-09 2022-07-20 Caribou Biosciences, Inc. Crispr abasic restricted nucleotides and crispr accuracy via analogs
CA3166430A1 (en) * 2020-02-05 2021-08-12 Ryan T. Gill Compositions and methods for targeting, editing or modifying human genes
US20230087228A1 (en) * 2020-02-24 2023-03-23 The Broad Institute, Inc. Novel type iv and type i crispr-cas systems and methods of use thereof
US20230340538A1 (en) 2020-04-08 2023-10-26 Astrazeneca Ab Compositions and methods for improved site-specific modification
WO2021226558A1 (en) 2020-05-08 2021-11-11 The Broad Institute, Inc. Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence
CN115956120A (zh) * 2020-05-12 2023-04-11 马萨诸塞大学 用于crispr基因组编辑的修饰的指导rna
US20250027078A1 (en) * 2020-10-19 2025-01-23 Caribou Biosciences, Inc. Dna-containing polynucleotides and guides for crispr type v systems, and methods of making and using the same
CN112301162B (zh) * 2020-10-22 2023-09-22 清华-伯克利深圳学院筹备办公室 同时检测dna病毒和rna病毒的病毒核酸检测方法
US20240182890A1 (en) 2021-04-07 2024-06-06 Astrazeneca Ab Compositions and methods for site-specific modification
GB202509407D0 (en) * 2021-09-22 2025-07-30 Verve Therapeutics Inc Gene editing of pcsk9 or angptl3 and compositions and methods of using same for treatment of disease
EP4408996A2 (en) 2021-09-30 2024-08-07 Astrazeneca AB Use of inhibitors to increase efficiency of crispr/cas insertions
CN117999481A (zh) 2021-10-26 2024-05-07 卡里布生物科学公司 核酸外切酶偶联实时核酸内切酶活性测定
IL312921A (en) * 2021-12-07 2024-07-01 Caribou Biosciences Inc A method for capturing CRISPR endonuclease cleavage products
EP4499829A2 (en) * 2022-03-29 2025-02-05 Accuredit Therapeutics (Suzhou) Co., Ltd. Compositions and methods for treatment of transthyretin amyloidosis
KR20250005083A (ko) * 2022-04-13 2025-01-09 카리부 바이오사이언시스 인코포레이티드 Crispr v형 시스템의 치료학적 응용
WO2023224327A1 (ko) * 2022-05-20 2023-11-23 한국생명공학연구원 오토라이신을 활용한 미세조류의 유전자 교정 효율을 증대시키기 위한 시스템 및 방법
EP4504764A1 (en) 2022-05-26 2025-02-12 Caribou Biosciences, Inc. Cytokine-receptor fusions for immune cell stimulation
WO2023240042A1 (en) 2022-06-06 2023-12-14 Caribou Biosciences, Inc. Treatment of autoimmune diseases with engineered immune cells
EP4578945A4 (en) 2022-08-26 2025-12-17 Guangzhou Reforgene Medicine Co Ltd CRISPR-CAS13 SYSTEM AND ITS USE
IL319598A (en) 2022-09-30 2025-05-01 Caribou Biosciences Inc Anti-ROR1 chimeric antigen receptors, CAR-NK cells and related methods
EP4584283A1 (en) 2022-11-14 2025-07-16 Caribou Biosciences, Inc. Anti-cll-1 chimeric antigen receptors, engineered cells and related methods
EP4414452A1 (en) * 2023-02-13 2024-08-14 Universidad de Granada Dual-guide rna composition for executing a single-guide rna crispr-associated system
WO2024201368A1 (en) 2023-03-29 2024-10-03 Astrazeneca Ab Use of inhibitors to increase efficiency of crispr/cas insertions
AU2024265453A1 (en) 2023-05-01 2025-09-25 Caribou Biosciences, Inc. Treatment of autoimmune diseases with bcma-targeting engineered immune cells
AU2024270764A1 (en) 2023-05-15 2025-12-04 Nchroma Bio, Inc. Compositions and methods for epigenetic regulation of hbv gene expression
WO2025006880A1 (en) 2023-06-29 2025-01-02 Caribou Biosciences, Inc. Diagnostic and therapeutic methods for use with ror1 antagonists
WO2025024676A1 (en) 2023-07-26 2025-01-30 Caribou Biosciences, Inc. In vitro validation methods for cd19-targeting cell therapies
CN119614679A (zh) * 2023-09-14 2025-03-14 厦门大学 一款通用型核酸检测平台
WO2025064930A1 (en) * 2023-09-20 2025-03-27 Emory University Nucleic acid hairpin based triggered hydrogels and uses thereof
WO2025117745A1 (en) 2023-12-01 2025-06-05 Caribou Biosciences, Inc. Methods and compositions for improving precision of endonuclease-mediated genome editing
WO2025193609A1 (en) 2024-03-11 2025-09-18 Caribou Biosciences, Inc. Methods and compositions for cost-effective assessment of nucleic acid transcripts and isoforms in cells
WO2025193386A1 (en) 2024-03-13 2025-09-18 Caribou Biosciences, Inc. Treatment regimens for autoimmune disease with cd19-targeting engineered immune cells
WO2026024468A1 (en) 2024-07-26 2026-01-29 Caribou Biosciences, Inc. Modular linked chimeric antigen receptors

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4217344A (en) 1976-06-23 1980-08-12 L'oreal Compositions containing aqueous dispersions of lipid spheres
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4186183A (en) 1978-03-29 1980-01-29 The United States Of America As Represented By The Secretary Of The Army Liposome carriers in chemotherapy of leishmaniasis
US4261975A (en) 1979-09-19 1981-04-14 Merck & Co., Inc. Viral liposome particle
US4485054A (en) 1982-10-04 1984-11-27 Lipoderm Pharmaceuticals Limited Method of encapsulating biologically active materials in multilamellar lipid vesicles (MLV)
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5049386A (en) 1985-01-07 1991-09-17 Syntex (U.S.A.) Inc. N-ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)Alk-1-YL-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4946787A (en) 1985-01-07 1990-08-07 Syntex (U.S.A.) Inc. N-(ω,(ω-1)-dialkyloxy)- and N-(ω,(ω-1)-dialkenyloxy)-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4897355A (en) 1985-01-07 1990-01-30 Syntex (U.S.A.) Inc. N[ω,(ω-1)-dialkyloxy]- and N-[ω,(ω-1)-dialkenyloxy]-alk-1-yl-N,N,N-tetrasubstituted ammonium lipids and uses therefor
US4774085A (en) 1985-07-09 1988-09-27 501 Board of Regents, Univ. of Texas Pharmaceutical administration systems containing a mixture of immunomodulators
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5264618A (en) 1990-04-19 1993-11-23 Vical, Inc. Cationic lipids for intracellular delivery of biologically active molecules
AU7979491A (en) 1990-05-03 1991-11-27 Vical, Inc. Intracellular delivery of biologically active substances by means of self-assembling lipid complexes
US7256322B2 (en) 1999-10-01 2007-08-14 Pioneer Hi-Bred International, Inc. Wuschel (WUS) Gene Homologs
AU2005210493B2 (en) 2004-02-02 2009-06-04 Pioneer Hi-Bred International, Inc. AP2 domain transcription factor ODP2 (ovule development protein 2) and methods of use
ES2541693T3 (es) * 2007-03-02 2015-07-23 Dupont Nutrition Biosciences Aps Cultivos con resistencia mejorada a fagos
CN103038338B (zh) 2010-05-10 2017-03-08 加利福尼亚大学董事会 核糖核酸内切酶组合物及其使用方法
GB201122458D0 (en) 2011-12-30 2012-02-08 Univ Wageningen Modified cascade ribonucleoproteins and uses thereof
WO2013141680A1 (en) 2012-03-20 2013-09-26 Vilnius University RNA-DIRECTED DNA CLEAVAGE BY THE Cas9-crRNA COMPLEX
US9637739B2 (en) 2012-03-20 2017-05-02 Vilnius University RNA-directed DNA cleavage by the Cas9-crRNA complex
EP4570908A3 (en) * 2012-05-25 2025-10-22 The Regents of the University of California Methods and compositions for rna-directed target dna modification and for rna-directed modulation of transcription
ES2757623T3 (es) 2012-07-25 2020-04-29 Broad Inst Inc Proteínas de unión a ADN inducibles y herramientas de perturbación genómica y aplicaciones de las mismas
PT2784162E (pt) 2012-12-12 2015-08-27 Broad Inst Inc Engenharia de sistemas, métodos e composições guia otimizadas para a manipulação de sequências
EP2784162B1 (en) 2012-12-12 2015-04-08 The Broad Institute, Inc. Engineering of systems, methods and optimized guide compositions for sequence manipulation
US8697359B1 (en) 2012-12-12 2014-04-15 The Broad Institute, Inc. CRISPR-Cas systems and methods for altering expression of gene products
WO2014093595A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas component systems, methods and compositions for sequence manipulation
DK3064585T3 (da) 2012-12-12 2020-04-27 Broad Inst Inc Konstruering og optimering af forbedrede systemer, fremgangsmåder og enzymsammensætninger til sekvensmanipulation
WO2014093701A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Functional genomics using crispr-cas systems, compositions, methods, knock out libraries and applications thereof
WO2014093694A1 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Crispr-cas nickase systems, methods and compositions for sequence manipulation in eukaryotes
WO2014093622A2 (en) 2012-12-12 2014-06-19 The Broad Institute, Inc. Delivery, engineering and optimization of systems, methods and compositions for sequence manipulation and therapeutic applications
DK2931898T3 (en) 2012-12-12 2016-06-20 Massachusetts Inst Technology CONSTRUCTION AND OPTIMIZATION OF SYSTEMS, PROCEDURES AND COMPOSITIONS FOR SEQUENCE MANIPULATION WITH FUNCTIONAL DOMAINS
EP2971167B1 (en) 2013-03-14 2019-07-31 Caribou Biosciences, Inc. Compositions and methods of nucleic acid-targeting nucleic acids
KR102405549B1 (ko) * 2013-03-15 2022-06-08 더 제너럴 하스피탈 코포레이션 Rna-안내 게놈 편집을 위해 특이성을 증가시키기 위한 절단된 안내 rna(tru-grnas)의 이용
AU2014281026B2 (en) * 2013-06-17 2020-05-28 Massachusetts Institute Of Technology Delivery, engineering and optimization of tandem guide systems, methods and compositions for sequence manipulation
MX363842B (es) * 2013-08-22 2019-04-05 Du Pont Métodos para producir modificaciones genéticas en un genoma vegetal sin incorporar un marcador transgénico seleccionable, y composiciones de éstas.
WO2015089277A1 (en) * 2013-12-12 2015-06-18 The Regents Of The University Of California Methods and compositions for modifying a single stranded target nucleic acid
LT3250691T (lt) 2015-01-28 2023-09-11 Caribou Biosciences, Inc. Crispr hibridiniai dnr/rnr polinukleotidai ir naudojimo būdai

Also Published As

Publication number Publication date
JP7038079B2 (ja) 2022-03-17
GB201712504D0 (en) 2017-09-20
US9580701B2 (en) 2017-02-28
US20200056209A1 (en) 2020-02-20
US20170349915A1 (en) 2017-12-07
FI3250691T3 (fi) 2023-08-24
US20210371883A1 (en) 2021-12-02
DK3250691T5 (da) 2024-10-07
GB2550745A (en) 2017-11-29
MX2024015281A (es) 2025-02-10
IL273147B (en) 2021-12-01
IL262042B (en) 2020-03-31
US20160362668A1 (en) 2016-12-15
AU2021202913A1 (en) 2021-06-03
US9868962B2 (en) 2018-01-16
ZA201705174B (en) 2018-12-19
AU2023202056B2 (en) 2023-05-18
RU2017130143A (ru) 2019-02-28
US20250376700A1 (en) 2025-12-11
US20160215300A1 (en) 2016-07-28
EP3250691A1 (en) 2017-12-06
WO2016123230A1 (en) 2016-08-04
SG11201705788TA (en) 2017-08-30
DK3250691T3 (da) 2023-09-18
US9688972B2 (en) 2017-06-27
CN111518811A (zh) 2020-08-11
EP4257690A2 (en) 2023-10-11
US9650617B2 (en) 2017-05-16
US20170226534A1 (en) 2017-08-10
HUE063813T2 (hu) 2024-02-28
US9771601B2 (en) 2017-09-26
SG10201804715WA (en) 2018-07-30
KR20190008998A (ko) 2019-01-25
RS64527B1 (sr) 2023-09-29
ZA201803945B (en) 2019-09-25
EP3250691B9 (en) 2023-08-02
CA3060508A1 (en) 2016-08-04
IL253608B (en) 2019-02-28
AU2016211517B2 (en) 2021-05-13
KR20190112855A (ko) 2019-10-07
HRP20231022T1 (hr) 2023-12-08
AU2023202056A1 (en) 2023-05-04
ES2955957T3 (es) 2023-12-11
LT3250691T (lt) 2023-09-11
IL273147A (en) 2020-04-30
SG10201906513WA (en) 2019-09-27
CA3060508C (en) 2023-08-29
CN107810270A (zh) 2018-03-16
IL288263A (en) 2022-01-01
BR112017016080A2 (pt) 2018-04-03
JP6835726B2 (ja) 2021-02-24
AU2021202913B2 (en) 2023-02-16
KR20220159498A (ko) 2022-12-02
RU2713328C2 (ru) 2020-02-04
HK1245839A1 (en) 2018-08-31
US20200354750A1 (en) 2020-11-12
EP3250691B1 (en) 2023-06-21
JP2018503386A (ja) 2018-02-08
CA2975166C (en) 2020-01-14
NZ733702A (en) 2022-04-29
PL3250691T3 (pl) 2023-11-27
JP2019162140A (ja) 2019-09-26
US20180142263A1 (en) 2018-05-24
US10988781B2 (en) 2021-04-27
SMT202300341T1 (it) 2023-11-13
US11236364B2 (en) 2022-02-01
EP4257690A3 (en) 2024-03-27
US10519468B2 (en) 2019-12-31
IL288263B (en) 2022-07-01
RU2017130143A3 (enExample) 2019-07-17
US20170121694A1 (en) 2017-05-04
MX2017009506A (es) 2017-11-02
KR102319192B1 (ko) 2021-10-28
CA2975166A1 (en) 2016-08-04
IL253608A0 (en) 2017-09-28
BR112017016080B1 (pt) 2024-02-20
US20230193324A1 (en) 2023-06-22
US11459588B2 (en) 2022-10-04
KR20170126875A (ko) 2017-11-20
IL262042A (en) 2018-11-29
AU2016211517A1 (en) 2017-08-03
PT3250691T (pt) 2023-09-25

Similar Documents

Publication Publication Date Title
IL288263A (en) CRISPR DNA/RNA hybrid polynucleotides and methods for using them
ZA201905536B (en) Methods for providing single-stranded rna
SG11201608503UA (en) Methods and compositions for modifying genomic dna
IL251896A0 (en) A method for enriching cancerous DNA in the bloodstream
EP3192869A4 (en) Isolated oligonucleotide and use thereof in nucleic acid sequencing
SG11201605906UA (en) Muscle-specific nucleic acid regulatory elements and methods and use thereof
SG11201609211VA (en) Genomic sequence modification method for specifically converting nucleic acid bases of targeted dna sequence, and molecular complex for use in same
LT3359671T (lt) Dnr vektoriai, transpozonai ir transpozazės, skirti eukariotinio genomo modifikacijai
ZA201801947B (en) Compounds as dna probes, methods and applications thereof
GB201405226D0 (en) Nucleic acid preparation method
IL251701A0 (en) Oligonucleotides for editing genomic DNA
EP3102677A4 (en) Genomic dna extraction reagent and method
SG11201704744QA (en) Methods and kits for purifying plasmid dna
EP3228707A4 (en) Vector containing centromere dna sequence and use thereof
SG11202004757RA (en) Dna polymerases
PL3423594T3 (pl) Oligonukleotydy i sposoby ich przygotowania
EP3259355A4 (en) Methods related to dna sequencing
GB201419225D0 (en) Method for the enrichment of circulating tumor DNA
GB201503845D0 (en) Nucleic acid analysis
GB201403360D0 (en) Nucleic acids and uses thereof
GB201403359D0 (en) Nucleic acids and uses thereof